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Abstract
Vogt-Koyanagi-Harada disease (VKHD) is a rare granulomatous inflammatory disease that affects pigmented structures,
such as eye, inner ear, meninges, skin and hair. This disease is mainly a Th1 lymphocyte mediated aggression to
melanocytes after a viral trigger in the presence of HLA-DRB1*0405 allele. The absence of ocular trauma or
previous intraocular surgery sets VKHD appart from sympathetic ophthalmia, its main differential diagnosis. The
disease has an acute onset of bilateral blurred vision with hyperemia preceded by flu-like symptoms. The acute
uveitic stage is characterized by a diffuse choroiditis with serous retinal detachment and optic disc hyperemia
and edema. Fluorescein angiography in this phase demonstrates multiple early hyperfluorescent points. After the
acute uveitic stage, ocular and integumentary system pigmentary changes may appear. Ocular findings may be
accompanied by lymphocytic meningitis, hearing impairment and/or tinnitus in a variable proportion of patients.
Prompt diagnosis followed by early, aggressive and long-term treatment with high-dose corticosteroids is most
often ensued by good visual outcomes. However, some patients may experience chronic uveal inflammation with
functional eye deterioration. The current review discusses the general features of VKHD, including epidemiology,
classification into categories, differential diagnosis and current therapeutic approaches.
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Background
Vogt-Koyanagi-Harada disease (VKHD), initially de-
scribed as an uveomeningoencephalitic syndrome, is a
systemic granulomatous autoimmune disease that tar-
gets melanocyte-rich tissues, such as the eye, inner ear,
meninges, skin and hair [1].
In 1906, Alfred Vogt in Switzerland first described a
patient with premature whitening of eyelashes of sudden
onset and bilateral subacute iridocyclitis. Twenty years
later, Harada (1926) reported a case series with bilateral
serous retinal detachment in association with cerebro-
spinal fluid (CSF) pleocytosis. Shortly thereafter (1929),
Koyanagi published a review article associating unequivo-
cally the posterior eye involvement with auditory and
integumentary manifestations. In 1932, Babel suggested
that these cases represented a single entity, which was
then named Vogt-Koyanagi-Harada Disease [2].
It is speculated that the renowned painter Francisco
José Goya y Lucientes (1746–1828) may have presented
the disease in his midcareer (1792). Its main features
were loss of vision and hearing, ringing in the ears,
vertigo, weakness on one side of the body, confusion,
abdominal pain and malaise. Goya recovered most of his
eyesight, but remained permanently deaf [3].
Thus, VKHD is an uncommon multisystem inflamma-
tory disease characterized by panuveitis, often associated
with neurologic and cutaneous manifestations, including
headache, hearing loss, vitiligo and poliosis.
Epidemiology
VKHD is an important cause of noninfectious uveitis
affecting, more frequently, individuals of pigmented skin,
such as Asians, Middle Easterners, Hispanics and Native
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Americans. It is very infrequent among persons of African
descent [4].
The incidence of VKHD varies. Among all cases of
uveitis, it was estimated to represent approximately 7 %
in Japan [5], 1–4 % in the United States [6] and 3 % in
Brazil [7, 8]; thus ranking, along with Behçet’s disease, as
the most prevalent causes of noninfectious uveitis in
Brazil [7]. In China, VKHD is one of the most common
uveitis entities [9]. In the United States, the incidence of
VKHD is approximately 1.5 to 6 per 1 million patients,
while in Japan it is seen in approximately 800 new pa-
tients each year [1, 10].
Most studies have found that women were affected
more frequently than men and that most patients were
in the second to fifth decades of life at the onset of the
disease. However, children [11, 12] and the elderly may
also be affected [13, 14]. Women account for 55 to 78 %
of VKHD patients in the United States and approxi-
mately 38 % in Japan, showing a global variation in
gender predilection [1, 10].
Pathogenesis
The exact etiology of VKHD is still a matter of enquiry.
The most accepted mechanism involves an autoimmune
aggression against antigens associated with melanocytes in
a genetically susceptible individual after a virus infection
trigger (Fig. 1). Genome of viruses from the herpes family
(Epstein-Barr virus) was detected by PCR (Polymerase
Chain Reaction) in the vitreous from VKHD patients [15].
Sugita et al. described that T cells from peripheral blood
and intraocular fluid from patients with VKHD cross-
reacted with tyrosinase protein and with highly homolo-
gous cytomegalovirus specific sequences [16].
Histopathologic findings and in vitro experiments
demonstrated the role of CD4+ T lymphocytes. Matsuda
demonstrated, in eyes globes from patients with VKHD, a
close interaction between lymphocytes and melanocytes
[17]. In vitro, uveal pigment inhibited leukocyte migration
of peripheral blood mononuclear cells (PBMC) from
patients with VKHD [18], and both CD4+ and CD8+ T
lymphocytes were cytotoxic against melanocytes in vitro
[19]. Moreover, Norose at al. described cytotoxicity dis-
played by lymphocytes from PBMC and CSF of patients
with VKHD against the B-36 melanoma cell line [20]. Mc-
Clellan et al. also found that IL-2 dependent T cells from
VKHD patients reacted specifically with normal melano-
cytes as well as melanoma cells [21].
As suggested by these studies, the immune response
is aimed at proteins associated with melanocytes.
Melanocyte-specific proteins, shown to have a major
role in differentiation, such as tyrosinase (TYR), tyrosinase-
related protein 1 (TRP1) and 2 (TRP2), MART-1/Melan A
and Pmel17/gp100, are also expressed in human melanoma
cell lines and were recognized by T lymphocytes of patients
with melanoma and are involved in tumor regression [22].
PBMCs from patients with VKHD recognized peptides
derived from tyrosinase family proteins involved in melanin
synthesis [23–26]. Peptides derived from TYR, TRP1, and
TRP2 induced an autoimmune disease in rats that resem-
bles VKHD [27], making these melanocyte proteins candi-
date autoantigens for VKHD. Altogether, these data
indicate that patients with VKHD are sensitized to melano-
cyte epitopes and display a peptide-specific Th1 cytokine
response [25, 26].
Sakamoto et al., in an immunohistochemical study of
eyes affected by VKHD, revealed an increased T helper/
T suppressor cells ratio and CD25+ and CD26+ T lym-
phocytes within choroidal inflammatory focii. These
authors also observed class II major histocompatibility
complex (MHC) expression in choroidal melanocytes
Fig. 1 Hypothetical scheme of VKHD pathogenesis. Courtesy of Arquivos Brasileiros de Oftalmologia – Damico, F.M., et al., New insights into Vogt-Koyanagi-
Harada disease. Arq Bras Oftalmol, 2009. 72 [3]: p. 413-20 [39]
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and endothelium of choriocapillaris [28]. Inomata and
Sakamoto demonstrated a remarkable disappearance of
choroidal melanocytes in VKHD eyes [29]. These find-
ings suggested that T cell-mediated immune process
against melanocytes that express class II MHC play a
pathogenic role in VKHD.
Several studies have demonstrated that HLA-DR4 (hu-
man leukocyte antigen) is strongly associated with VKHD
patients of different ethnic groups, e.g. North Americans
[30], Japanese [31–33], Chinese [34], Hispanics [35] and
Brazilian [36]. In Japanese subjects, HLA-DRB1*0405 and
DRB1*0410 combined susceptibility was robust [relative
risk (RR) = 100] [32]. In ethnically heterogeneous Brazilian
subjects, HLA-DRB1*0405 was also the predominant
allele, with a RR of 12 [36]. Thus, HLA-DRB1*0405 plays
a pivotal role in several populations. Besides HLA-DR
involvement in VKHD, recently accumulating evidence
has demonstrated association of non-HLA genetic factors
in VKHD, i.g. cytotoxic T-lymphocyte antigen 4 gene,
interleukin genes, macrophage migration inhibitory factor
gene and osteopontin gene [37]. More recently, on genome
wide analysis, three loci were associated with VKHD sus-
ceptibility IL23R-C1orf141, rs117633859; ADO-ZNF365-
EGR2, rs442309 and HLA-DRB1/DQA1, rs3021304 [38].
Thus, immunogenetics rather than skin pigmentation may
be the clue for disease susceptibility.
Helper T cell subsets producing Th1 cytokines (inter-
feron-gamma and interleukin-2) after melanocyte derived
peptides may produce pathological changes in VKHD, such
as the granulomatous choroid inflammation in acute phase
of VKHD [39–41]. Also of importance, are the cytokines
associated with the pro-inflammatory IL-17-producing T
helper (Th17) cell, i.g. IL-23, IL-7 and IL-21 [42–44]. In ac-
tive VKHD patients, increased IL-17 may also result from a
decreased IL-27 expression [42, 45]. By contrast, IL-10 and
TGF-β regulatory cytokines are associated with the reso-
lution of active inflammation [46]. Active VKHD has also
been associated with a diminished function of regulatory T
cells (CD4+CD25high regulatory) [47]. Concerning innate
inflammatory cytokines such as IL-6, Chen et al. described
significantly higher levels in aqueous humor of VKHD
cataract patients as compared to age-related cataract
patients [5, 48].
Cellular and humoral autoimmunity against retinal
components have also been demonstrated in patients
with VKHD [49–51], as well an anti-Ro/SSA reactivity,
in a small percentage of patients [52]. In vitro lympho-
cytic proliferation in the presence of retinal antigens has
shown contradictory results. Naidu et al. showed a posi-
tive response to retinal S antigen and interphotoreceptor
retinoid binding protein (IRBP) in active untreated pa-
tients [49]. Conversely, de Smet et al. detected no such
response in chronic VKHD patients [50]. Thus, auto-
reactivity against retinal proteins seem to differ upon
disease stages, i.e., acute vs. chronic. Autoantibodies
against photoreceptor outer segments and Müller cells
in the sera of VKHD patients have been detected [51].
However, these antibodies could represent a secondary
response, which follows the retinal damage in VKHD
patients.
Histopathologic aspects
Histopathological features of VKHD vary according to the
stage of disease [53]. The primary pathological feature of
VKHD is, however, diffuse thickening of the uveal tract
(more prominent in the juxtapapillary choroid). In the
acute stage there is a granulomatous process.
In the acute uveitic stage, it is of note a diffuse
lymphocytic infiltration with focal aggregates of epitheli-
oid cells and multinucleated giant cells containing pig-
ment devoid apparent choroidal necrosis [53]. Choroidal
infiltrate consists of T lymphocytes, which exhibit the
markers of helper (CD4+) and suppressor/cytotoxic cells,
along with melanocytes expressing class II major histo-
compatibility complex molecules. An eosinophilic exudate
with proteinaceous material may be detected underlying
the detached retina. While the retinal pigment epithelium
(RPE) may appear unharmed using light microscopy, oc-
casional lymphocytes below the RPE may be observed.
Focal collections of hyperplastic/modified RPE, macro-
phages, epithelioid cells and lymphocytes located between
RPE and Bruch’s membrane may form the Dalen-Fuchs
nodules [53].
During the convalescent stage, there is a nongranulo-
matous inflammation, which consists hispathologically
of a mild to moderate non-granulomatous inflammatory
cell infiltrate with focal aggregates of lymphocytes and
occasional macrophages. The loss of melanin granules of
choroidal melanocytes renders a pale, depigmented
aspect to the choroid. Thus, the “sunset glow fundus”
appearance in the convalescent stage results from
immune-mediated insult to choroidal melanocytes. The
RPE may assume either a relatively normal appearance or
be focally destroyed, with subsequent chorioretinal adhe-
sions, which correspond to the small atrophic nummular
hypopigmented lesions observed in the mid periphery of
the fundus [53].
During chronic recurrent stage, a granulomatous chor-
oiditis with damage of choriocapillaris is observed. Fur-
thermore, one may observe a granulomatous infiltrate
with less prominent diffuse uveal thickening than that
observed in the acute stage. Chorioretinal adhesions
with atrophy and/or proliferation of RPE are frequent.
Focal areas of hyperpigmentation in depigmented fundi
are the consequence of RPE proliferation. This may be
accompanied by subretinal neovascularization and ele-
vated pigmented lesions. The hyperplasic RPE can be
reorganized and form areas of subretinal fibrosis. Besides
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these RPE changes, photoreceptor degeneration and
gliosis can also be observed. In fact, chronic and recur-
rent inflammation in the choroid, as noted in VKHD,
may stimulate proliferation of retinal pigment epithelial
cells [53, 54]. Unlike other stages, there is involvement
of the choriocapillaris [53].
In other tissues affected by VKHD (skin and central
nervous system (CNS)), there are similar findings:
cellular infiltrate composed of T lymphocytes, espe-
cially CD4+ T cells, and macrophages containing mel-
anin granules [53]. On the other hand, skin lesions of
VKHD patients were analysed with electron micros-
copy and it was possible to demonstrate that, at the
periphery of the depigmented lesion, the melanocytes
had several subcellular abnormalities, ie, vacuolization of
the cytoplasm, aggregation of melanosomes, autophagic
vacuoles, fatty degeneration, pyknosis or homogeneous
cytoplasmic degeneration, and others. And even absence
of melanocytes could be observed [55].
Table 1 describes the main histopathological aspects
and their clinical correspondents in Vogt-Koyanagi-
Harada disease.
Diagnostic criteria
The diagnosis of VKHD is primarily based on clinical
features. Several criteria have been proposed to clarify
the diagnostic approach, including the American Uveitis
Society (AUS) in 1978 and the Sugiura’s Criteria in
1976. The AUS adopted the following diagnostic
criteria [4, 56]:
 No history of ocular trauma and/or surgery;
 At least three of the following four signs:
a) Bilateral chronic iridocyclitis;
b) Posterior uveitis (multifocal exudative retinal or
RPE detachments; disc hyperemia or edema; or
“sunset glow fundus”, which is a yellow-orange
appearance of the fundus due to depigmentation
of the RPE and choroid);
c) Neurologic signs (tinnitus, neck stiffness, cranial
nerve or central nervous system symptoms or
cerebral spinal fluid pleocytosis);
d) Cutaneous findings (alopecia, poliosis or vitiligo).
The AUS criteria come short in setting appart acute
and chronic cases. Another limitation consists in inad-
equate consideration of acute cases, as two of the four
cardinal signs characteristically occur in the convales-
cent/chronic stages of disease. Moreover, fluorescein
(FA) and indocyanine angiography (ICGA), as well
ultrasonographic findings were not taken into account
by the AUS criteria. As such, neither chronology nor
complementary exams were taken into account.
Sugiura et al. proposed another set of diagnostic cri-
teria for VHKD. This system is seldom used outside
Japan once CSF analysis is mandatory [4, 57, 58].
More comprehensive criteria were put forth in 2001
by the International Nomenclature Committee, namely
the Revised Diagnostic Criteria (RDC). The RDC classi-
fies disease into three categories: complete, incomplete
and probable VKH based on the presence of extraocular
findings (Table 2) [59]. By considering early and late
ocular manifestations, patients may be diagnosed regard-
less of time elapsed to presentation. However, ancillary
examinations (i.e. ICGA [60, 61] and optical coherence
tomography (OCT) [62] were not taken into account.
Also of note, the RDC does not consider follow up
period and treatment; both parameters may interfere on
extraocular manifestations incidence [63].
Recently, da Silva et al. demonstrated a correlation be-
tween fundus changes and parameters of the full-field
electroretinography (ffERG) in patients with VKHD at
late stage (with more than 6 months duration of the dis-
ease, which includes chronic and convalescent stages).
Fundus parameters were used to propose an analytic
Table 1 Histopathological aspects and their clinical correspondents
in Vogt-Koyanagi-Harada disease [53, 54]
Histopathologic findings Clinical correspondents/Ancillary
exams
Diffuse granulomatous inflammatory
infiltrate of choroid (lymphocytes,
macrophages, epithelioid cells,
multinucleated giant cells)
In the acute and chronic stages:




Dark dots (?) (ICGA)
Dalen-Fuchs nodules (conglomerate
between Bruch’s membrane and RPE
consisting of lymphocytes, pigment-
laden macrophages, epithelioid cells,
and proliferated RPE)
In the acute stage:




In the convalescent stage:
“Sunset glow fundus” (diffuse
depigmentation)
Focal RPE atrophy with retinal
and choroidal adhesion
In the convalescent stage:
Atrophic nummular
hypopigmented lesions in the
mid periphery
Window defect in FA (OCT)
RPE hyperplasia In the convalescent stage:
Pigment clumps (OCT, FAF (?))
RPE hyperplasia without melanin
granules
Subretinal fibrosis (OCT)
Degenerated photoreceptor Elipsoidal layer disruption (OCT)
Abnormal (ERG)
US ultrasound, EDI-OCT enhanced depth imaging-optical coherence tomography,
ICGA indocyanine green angiography, RPE retinal pigment epithelium, FA fluorescein
angiography, FAF fundus autofluorescence imaging, ERG electroretinography
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framework for fundus changes in late-stage VKHD,
namely: diffuse pigmentary changes; nummular lesions;
pigment clumps and subretinal fibrosis. The correlation of
fundus severity and ffERG parameters indicates that fun-
dus changes may reflect functional abnormalities [64].
Lumbar puncture is useful in confirming the diagnosis of
VKHD in the acute stage only [44]. Given the large amount
of patients found to have auditory symptoms, audiological
testing is recommended in VKHD patients [65].
Clinical features
VKHD is classically divided into four stages: prodromic,
acute uveitic, convalescent and chronic/recurrent [1]. To
“stage” the disease may enable exchange information
rapidly between caregivers as to chronology of the dis-
ease which implies in treatment strategies.
Prodromal stage
The prodromal stage lasts a few days and mimics a viral in-
fection [1]. Patients may present with fever, headache, nau-
sea, vertigo, orbital pain, photophobia, tearing, tinnitus,
vertigo and neurologic symptoms. In this stage, cerebro-
spinal fluid may reveal pleocytosis [4, 59]. Extraocular
manifestations will be detailed in an appropriate following
section.
Acute uveitic stage
This typically occurs within 3 to 5 days of the pro-
dromal stage and lasts for several weeks. Patients may
experience acute blurring of vision in both eyes; in
30 % of patients, the involvement of the fellow eye oc-
curs after a few days [1, 4, 58]. The underlying patho-
logic process in its early stage is the occurrence of a
diffuse choroiditis. Features of this choroiditis are ex-
udative detachment of the neurosensory retina second-
ary to diffuse choroidal inflammation. Hyperemia and
edema of the optic disk are observed in about 47 % [4]
(Figs. 2 and 3). On FA there are multiple hyperfluores-
cent leaking dots (pinpoints), which become coalescent
due to accumulation of fluorescein in the subretinal
space (pooling of dye). This is a typical feature of the
acute uveitic stage.
Inflammation extends into the anterior segment to
varying degrees. Thus, patients with VKHD may have
acute bilateral granulomatous iridocyclitis with mutton
fat keratic precipitates, iris nodules and shallow anterior
chamber due to ciliary body edema and inflammation
and suprachoroidal fluid collection. This last feature
may lead to acute angle closure glaucoma.
In a Chinese retrospective study including 410 VKHD
patients, the posterior and anterior uveal involvement
were delineated as consecutive stages [66].
Meningeal involvement and auditory symptoms may
also be present during the acute uveitic stage, which
may last for weeks or even months.
Convalescent stage
The convalescent stage follows the acute uveitic stage,
usually a few months later. It is characterized by depig-
mentation of the integument and choroid. Findings may
include vitiligo, alopecia and poliosis. Sugiura described a
perilimbal depigmentation that occurs on the first month
after the uveitis onset and is observed mainly in Japanese
subjects (Sugiura’s sign) [57]. At this stage, varying degree
Table 2 Revised Diagnostic Criteria of Vogt-Koyanagi-Harada
disease proposed by the International Nomenclature Commitee
[59]
1. No history of penetrating ocular trauma or surgery preceding the
initial onset of uveitis.
2. No clinical or laboratory evidence suggestive of other ocular disease
entities.
3. Bilateral ocular involvement (a or b must be met, depending on the
stage of disease when the patient is examined):
a. Early manifestations of disease:
I. Evidence of diffuse choroiditis (with or without anterior uveitis,
vitreous inflammatory reaction or optic disc hyperemia), which may
manifest as (A) focal areas of subretinal fluid, or (B) bullous exudative
retinal detachments.
II. If equivocal fundus findings, then both:
A. Fluorescein angiography showing focal delayed choroidal
perfusion, multiple areas of pinpoint leakage, large placoid areas of
hyperfluorescence, pooling within subretinal fluid, and optic nerve
staining;
B. Ultrasonography showing diffuse choroidal thickening without
evidence of posterior scleritis.
b. Late manifestations of disease:
I. History suggestive of prior presence of early findings noted in 3a
and either (II) or (III) below, or multiple signs from (III) below:
II. Ocular depigmentation: either (A) sunset glow fundus or (B)
Sugiura sign.
III. Other ocular signs including (A) nummular chorioretinal
depigmented scars, or (B) retinal pigment epithelium clumping and/or
migration, or (C) recurrent or chronic anterior uveitis.
4. Neurological/auditory findings (may resolve by time of evaluation):
a. Meningismus (malaise, fever, headache, nausea, abdominal pain,
stiffness of the neck and back, or a combination of these factors); note
that headache alone is not sufficient to meet definition of meningismus.
b. Tinnitus
c. Cerebrospinal fluid pleocytosis
5. Integumentary findings (not preceding onset of central nervous




Complete VKHD: criteria 1–5 must be present
Incomplete VKHD: criteria 1–3 and either 4 or 5 must be present
Probable VKHD (isolated ocular disease): criteria 1–3 must be present
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Fig. 2 Acute uveitic stage: a and b: Right and left eye of a patient in the acute stage of Vogt-Koyanagi-Harada disease, presenting white- yellowish
deep round lesions, hyperemia and blurring of the optic disc and exudative retinal detachment; c and d: Early fluorescein angiography, showing
pinpoints and optic disc hyperfluorescence; e and f: Increase in pinpoints hyperfluorescence (arrows) and optic disc leakage; g and h: Coalescence
of pinpoints hyperfluorescence resulting in pooling of the contrast (arrows) in exudative retinal detachment areas
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of diffuse or localized depigmentation with areas of pig-
ment accumulation may be observed in the fundus. This
depigmentation occurs 2 to 3 months after the uveitic
stage; the change may be from brunette to blonde, or it
may present as an exaggerated reddish glow fundus [4, 54,
67], which is described as “sunset glow fundus” (Fig. 4).
Fundus appearance may have focal accumulation of
pigment in bands or in lumps, interspersed with areas of
pigment rarefaction. In the mid-periphery, there are mul-
tiple, well-defined hypopigmented white lesions.
Recurrent or chronic stage
This stage may interrupt the convalescent stage. About
17–73 % of patients may progress to recurrence or chron-
icity [1, 68]. Rubsamen and Gass reported recurrence rates
of 43 % within the first 3 months and 52 % within the first
6 months, often associated with rapid tapering of cortico-
steroids [10]. Recurrence mainly involves anterior seg-
ment, without clinically detectable posterior involvement.
However, recent studies have shown that there is a persist-
ent aggression to choroidal melanocytes, observed on
ICGA and OCT [61, 62, 69, 70].
Ocular complications can often be observed in conva-
lescent and chronic stages. The most frequent ocular
complications are cataract, glaucoma, choroidal neovas-
cularization and retinal/choroidal fibrosis.
Extraocular manifestations
Involvement of integument and the central nervous system
(CNS) may be present at various stages of the disease. The
frequency and severity of extraocular manifestations varies
by patients’ ethnic group, being more common in Asian
population (Table 3), and also by treatment adequacy.
CNS involvement
The prodromic stage (also called meningeal stage) oc-
curs due to the CNS involvement. During the acute
stage meningeal signs may also arise, such as neck stiff-
ness, confusion and headache. CSF pleocytosis is ob-
served in more than 80 % of cases, with a predominance
of lymphomononuclear cells, which may be present until
the eighth week of the onset of the disease [45]. Serious
meningeal-encephalic manifestations and focal neuro-
logical signs (i.e.cranial neuropathies, hemiparesis, apha-
sia, acute transverse myelitis and ciliary ganglionitis)
were also reported [4, 58, 71].
Fig. 3 OCT scans in the acute uveitic stage. a and c Fundoscopic aspect with optic disc swelling and hyperemia, besides multiple yellowish deep
round lesions and exudative retinal detachment. b OCT scan showing a bullous unique exudative retinal detachment with hyperreflective material
within the subretinal fluid (fibrin) and a strand continuous to the ellipsoid zone (arrow); d OCT scan of an exudative retinal detachment, with multiple
compartments (asterisk) separated by membranous strutures
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Inner ear involvement
Changes in the inner ear, such as dysacusis, hearing loss
and vertigo, have been observed in 70 % of patients, es-
pecially during the prodromal stage. Tinnitus is present
in 42 % [65]. The hearing loss pattern is typically coch-
lear at high frequencies with improvement in 2 to
3 months [63]. Vestibular dysfunction is uncommon.
Skin and appendages involvement
Cutaneous findings usually develop during the chronic
or convalescent stage of the disease and include vitiligo,
alopecia and poliosis of the lashes, eyebrows and scalp
hair (Fig. 5). Vitiligo can be found in 10 to 63 % of pa-
tients [72]. The skin of the back or buttocks seems to be
the initial or main anatomic area involved [73].
Sugiura’s sign (perilimbal vitiligo) is the earliest depig-
mentation to occur, presenting itself one month after the
uveitic stage [74].
Differential diagnosis
The main differential diagnosis of VKHD is sympathetic
ophthalmia, the latter being necessarily preceded by ocular
penetrating trauma and/or previous intraocular surgery.
Other conditions that may mimic VKHD are represented
in Table 4 [1, 75–82].
Sympathetic ophthalmia is histopathologically identical
to VKHD and can present in a similar fashion with rapid,
bilateral visual loss associated with anterior segment
inflammation, choroidal thickening, disc hyperemia or
edema and serous retinal detachments. Nevertheless, the
definition of sympathetic ophthalmia requires previous
penetrating trauma or intraocular surgery [1, 83].
Acute posterior multifocal placoid pigment epithelio-
pathy is a rare inflammatory ocular disease, which affects
the choriocapillaris, the RPE and the outer retina in pre-
viously healthy and young patients. There is a sudden
and painless loss of central visual acuity (VA), unilateral
or bilateral, after a viral prodrome, with multiple creamy
white lesions, which can evolve to chorioretinal scars.
Usually, there is mild or no reaction in the vitreous. FA
typically shows early hypofluorescence by blockage in
the site of lesions, followed by a late hyperfluorescence.
FA findings set VKHD appart from APMMPE. ICGA al-
lows the observation of the entire length of the choroidal
involvement as depicted by hypofluorescent lesions in
the mid and late phases. Both entities may present with
serous retinal detachments, which improve with cortico-
steroid treatment. Many authors describe CNS involve-
ment that can range from mild changes (as headache) to
severe diffuse cerebral vasculitis. Prognosis of APMMPE
is generally good with spontaneous and/or rapid reso-
lution of visual function. Some patients may experience
only partial visual recovery. Systemic treatment may be
indicated in cases with severe visual impairment and/or
CNS complications [75, 84–87].
Birdshot chorioretinopathy is a chronic, bilateral intra-
ocular inflammation, occurring more frequently in
Caucasians, after the fourth decade of life. The typical
presentation is mild yellowish-white lesions throughout
the entire posterior pole, cystoid macular edema (CME),
disc edema, vasculitis and chronic vitritis. There is mild
anterior segment inflammation. It has a chronic course
with periods of exacerbation and remission of the dis-
ease, with progressive loss of visual acuity. FA findings
Fig. 4 Right eye of a patient in the chronic stage. a: Fundoscopy with a mild depigmentation; b: OCT scan showing an increased choroidal thickness
of 444 μm; c and d: Indocyanine green angiography showing multiple dark dots (arrows) and an uneven background choroidal fluorescence visible at
the mid phase of ICGA
Table 3 Prevalence of extraocular manifestations in Vogt-
Koyanagi-Harada disease
Japan, 2007 [182] USA, 1991 [70] Brazil, 2009 [64]
N = 136 patients N = 48 patients N = 67 patients
Meningeal signs 80 % 67 % 18 %
Pleocytosis 90 % - -
Tinnitus 53 % 17 % 24 %
Alopecia 7 % 13 % 9 %
Poliosis 18 % 6 % 22 %
Vitiligo 13 % 10 % 16 %
VKHD categories
Complete 22 % - 15 %
Incomplete 65 % - 55 %
Probable 13 % - 30 %
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are not so evident while ICGA tends to show areas of
hypofluorescence that persist until the late phases. ERG
shows an impairment of rod and cone function. A
strong association with HLA-A29 was observed indicat-
ing involvement of autoimmune mechanisms in its
pathogenesis [78].
Retinal lesions found in multiple evanescent white dot
syndrome can be mistaken with VKHD. MEWDS is usu-
ally unilateral, affects young women and is characterized
by sudden and painless loss of visual acuity. A viral infec-
tion may be present in half of the cases. Characteristically,
there are numerous, multifocal yellowish-white lesions
found in the deep retina/RPE at the posterior pole. In the
fovea, there is a distinctive granular appearance. It tends
to behave in a self-limited fashion with patients recovering
visual acuity in a few weeks. There is usually none or min-
imal anterior chamber reaction, but vitreous cells may be
observed as well choroidal thickening [85]. FA shows
hyperfluorescence in the early and late phases, disc leak-
age and, occasionally, perivascular sheathing. ICGA re-
veals multiple round hypofluorescent points at the
posterior pole. There is enlargement of the blind spot on
visual field and reduced amplitude of ERG waves. Recur-
rences are uncommon [77].
Multifocal choroiditis and panuveitis is a chronic re-
lapsing inflammatory disease, characterized by multiple
choroidal lesions on the posterior pole, mid-periphery or
periphery, associated with vitritis and anterior chamber
reaction. Predominantly, it affects women between 20
and 60 years, in a bilateral and often asymmetrical fash-
ion. FA reveals initial hypofluorescence followed by
hyperfluorescence. Subretinal fibrosis and choroidal neo-
vascularization may be observed [88].
Posterior scleritis is an uncommon form of scleral in-
flammation and is twice as common in women as in
men. Thirty percent to 45 % of cases may be associated
with systemic diseases such as systemic vasculitis, auto-
immune diseases and lymphoma. Posterior scleritis can
also present with intense ocular pain, radiating to the
head, ears and jaw; redness; choroidal folds, exudative
retinal detachment, optic disc edema and choroidal de-
tachment. However, it is usually unilateral and not asso-
ciated with neurologic or dermatologic findings. Also,
unique to posterior scleritis is the ultrasonographic “T
sign,” or squaring of the interface between the optic
nerve and the sclera, indicating the presence of fluid in
the sub-Tenon’s space. Characteristically, there may also
be posterior scleral shell thickening and retrobulbar
edema. The FA appearance may be similar to the VKHD
[1, 79, 89].
Primary intraocular lymphoma is a subtype of non-
Hodgkin central nervous system lymphoma (CNSNHL),
with moderate to high malignancy, most commonly ob-
served in individuals over 60 years of age. It can affect the
vitreous, retina and optic nerve, presenting as a chronic
uveitis, little or partially responsive to corticosteroids ac-
companied by neurological signs and symptoms. Bilateral
involvement is common. The fundus may show multifocal
elevated subretinal and sub-RPE yellow lesions, involving
the posterior pole, associated with vitritis. Satellite lesions
may also be present, simulating hypopigmented lesions in
the mid-periphery. Generally, there is choroidal thickening
with/without associated with retinal detachment. FA shows
choroidal fluorescence blockage with late leakage at the site
of inflammatory lesions. Unlike VKHD there is extensive
focal early hyperfluorescence with dye pooling in the
detached retina region in later phases of the angiogram. In
patients with CNSNHL, 20 to 25 % have ocular involve-
ment and 56 to 85 % initially presenting ocular lymphoma
develop brain lymphoma. Thus, patients with uveitis and
Fig. 5 Poliosis of the lashes eyebrows and scalp hair
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neurological symptoms should be carefully examined with
CSF tap and neuroimaging (preferably magnetic resonance
imaging (MRI) with intravenous Gadollinium enhance-
ment). Diagnosis of intraocular lymphoma can be con-
firmed by vitreous, retinal and/or choroidal biopsies [76].
Central serous retinopathy (CSC) is an idiopathic condi-
tion characterized by the development of serous detach-
ment of the sensory retina and, in some cases, serous
detachments of the RPE. It occurs primarily in healthy men
between 25 and 55 years of age. In rare cases, these symp-
toms are accompanied by a migraine-like headache, which
could resemble the prodromal stage of VKHD. FA may
show different patterns, being the diffuse one more similar
to the VKHD findings: large areas of serous detachment
and extensive RPE changes. Bilateral CSC may have asym-
metric findings. FA show choroidal vascular abnormalities.
However, although the yellow-white exudates of VKHD
may appear similar to CSC, the granulamatous uveitis is
not usually seen in this condition. Besides that, it is very
important to differenciate these two patologies, since corti-
costeroids (the initial and main treatment of VKHD) could
increase the risk of developing CSC [90, 91].
Systemic arterial hypertension and pre-ecclampsia may
also result in serous retinal detachments. It is suspected
that choroidal vascular changes predominate when acute
elevation of blood pressure is present, whereas a more
gradual onset of hypertension results in retinal vascular
changes. Hypertensive choroidopathy may manifest as
Elschnig spots (ischemic infarcts of the RPE and hypo-
perfusion in the underlying choroid); subretinal exu-
dates; serous retinal detachment; fundus depigmentation
and optic disc edema [1, 92].
Besides that, the cutaneous manifestations should ex-
clude diagnosis such as Alezzandrini’s syndrome, alopecia
areata, vitiligo and piebaldism. Other immunomediated
sensorineural hearing loss should also be excluded such as
Cogan syndrome. Uncommon VKHD association with
cutaneous pigmented malignant melanoma [93], with
Chron’s disease [94, 95] and polycystic ovary syndrome
[96] among others have been described.
Ancillary ophthalmic examination
The diagnosis of VKHD is clinical (as no laboratory
marker identifies the presence thereof ) and is based on
the RDC to date (Table 2). Nevertheless, FA and ocular
ultrasonography (US) can help the diagnosis and follow-
up of atypical cases. ERG examination may be a useful
method to evaluate the functional implications of
VKHD. Recently, technological advances have allowed a
better evaluation of the retina and choroid with ICGA
and spectral domain OCT. In conjunction, these im-
aging modalities have added new parameters for detect-
ing and quantifying inflammation and may allow better
assessment of treatment efficacy.
Fluorescein angiography (FA)
Changes in FA during the acute uveitic stage are charac-
teristic [62, 97] and can help differentiate VKHD from
other conditions (Fig. 2). Initially, with active inflamma-
tion, FA reveals a delay in choroidal perfusion, causing
hypofluorescence of circumscribed areas poorly perfused.
The classical numerous hyperfluorescent pinpoints ap-
peared successively and could correspond to focal alter-
ations of the RPE. These hyperfluorescent dots gradually
enlarge and stain the surrounding subretinal fluid with
pooling of dye in the subretinal space. These focii of
hyperfluorescence coincide with areas of choroiditis.
Nearly 70 % of the patients may present with disc leakage
in the acute stage of disease [97]. In some cases, it is pos-
sible to observe areas of linear hypofluorescence, mostly
due to the presence of choroidal folds. Sheathing and ret-
inal vascular leakage are rare in contrast to birdshot chor-
ioretinopathy for instance. The presence and extent of
pinpoints may be employed in order to monitor the effi-
cacy of initial therapy with corticosteroids [62, 98].
In the convalescent stage, disc leakage and hyperfluor-
escent dots may also be observed in respectively 29 %
and in 14 % of patients [62, 98].
In chronic and recurrent stages, FA may show multiple
hyperfluorescent window defects coupled with areas of
hypofluorescence due to blockage without progressive
staining due to areas of damage to the RPE, rendering a
Table 4 Differential diagnosis of Vogt-Koyanagi-Harada disease
Sympathetic
ophthalmia




Acute posterior multifocal placoid pigment
epitheliopathy (APMPPE)
Birdshot chorioretinopathy
Multifocal choroiditis and panuveitis (MCP)












Bilateral diffuse melanocytic hyperplasia
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“moth eaten” aspect. Choroidal neovascularization (CNV),
retinochoroidal anastomoses and neovascularization of
the disc may also be present [62].
Indocyanine green angiography (ICGA)
ICGA is generally employed in the study of choroidal
vasculature and stroma. It may also contribute to the
understanding of the pathophysiology of chorioretinal
inflammatory disordes [99]. Herbort et al. reviewed the
characteristic ICGA signs in VKHD and described the
following signs [60–62]:
 Inflammatory choroidal vasculopathy may lead to
delay in choroidal perfusion in the early stages of
ICGA (2 to 3 min after dye injection), involving the
posterior pole and the whole periphery;
 An uneven background choroidal fluorescence
visible at the mid phase of ICGA is the result of
multiple hypofluorescent round lesions in the
choroidal stroma.
 Choroidal folds could appear hyperfluorescent in
ICGA.
 Early hyperfluorescence with leakage throughout the
choroidal stroma coupled with loss of large
choroidal vessels in the intermediate phase (fuzzy
vessels) leading to diffuse hyperfluorescence;
 Numerous hypofluorescent, evenly distributed focii
(dark dots) in the intermediate phase, that gradually
become isofluorescent in the late phase may
represent choroidal granulomas (Fig. 3);
 Optic disc hyperfluorescence.
At this point, it is worthy to mention that, till recently,
disease activity parameters in non-acute VKHD stage
were essentially clinical; nowadays, there is a trend to-
wards taking posterior segment imaging inflammatory
signs also into consideration as inflammation markers
and, consequently, as indicators of additional systemic
treatment.
Fundus autofluorescence (FAF)
FAF reflects functional and metabolic changes in RPE
visualizing lipofuscin (BL-FAF) or melanin or its com-
pounds (NIR-FAF). These two modalities of fundus au-
tofluorescence (FAF) differ according to the wavelength
employed i.e. FAF with short wavelength light or blue
(BL-FAF) and near-infrared light (NIR-FAF) emission.
Koizumi et al. described that areas of both BL- as well
as NIR-FAF hypoautofluorescence in five patients (ten
eyes) with acute VKHD corresponded to regions of ser-
ous retinal detachment. After resolution of subretinal
fluid, FAF demonstrated placoid regions of hyperauto-
fluorescence in the macula and peripapillary region,
which corresponded to hypofluorescence on ICGA. In
patients receiving initial corticosteroid pulsetherapy,
hyperautofluorescent areas resolved, while patients re-
ceiving delayed treatment tended to present persistent
areas of macular hyperautofluorescence [100] which may
be attributed to alterations in distribution of both, mel-
anin as well as lipofucsin.
Heussen et al., in a retrospective study in ten patients
(20 eyes) with chronic VKHD utilizing ultra-wide-field
FAF, demonstrated peripheral changes on FAF images
with no correspondence to color images, i.e. areas of
hypoautofluorescence, areas of hyperautofluorescence
and “lattice-like” pattern of FAF [101].
Thus, as VKHD may affect both the choroid as well as
the RPE, different FAF patterns in both BL- and NIR
modalities are not surprising.
Optical coherence tomography (OCT)
OCT has revealed unique features of multifocal serous
retinal detachment in acute VKHD with cystic spaces
and membranous structures continuous to the ellipsoid
zone (internal and external segments junction of the
photoreceptors). Splitting of retinal layers was visible
over the IS/OS line near cystoid spaces that involved the
fovea in 45 % of the examined eyes. All of these abnor-
mal features were seen below the line representing the
external limiting membrane, that is, in the outer photo-
receptor layer [102]. Some authors hypothesized that
these strands are formed by fibrin and disrupted outer
segment of the photorreceptors [102–104] Other OCT
findings in the acute stage are intraretinal edema, chor-
oidal folds or striations (RPE undulations), choroidal
hyperreflective dots, among others [105–107] (Fig. 3).
Prompt resolution of the retinal detachment is usually
observed in OCT after high-dose systemic corticosteroid
[103, 108]. Several OCT parameters have been associ-
ated with a worse prognosis, e.g. “splitting off” of outer
segments of the photoreceptor layer from the inner seg-
ments [102], height of serous retinal detachment [104],
RPE undulations [104].
OCT imaging in chronic stage VKHD showed RPE and
outer retinal changes. These coincided with histopatho-
logical findings, such as RPE cell clumping and damage to
outer- and inner- segment junction of photoreceptors.
Vasconcelos-Santos et al. studied patients with chronic
VKHD and “sunset glow” fundus. Spectral domain-OCT
demonstrated normal retinal architecture in regions of
“sunset glow fundus”, RPE/Bruch’s membrane’s thinning
in regions of atrophy and RPE/Bruch’s membrane thicken-
ing in areas overlying pigmented scars [109].
Enhanced-depth imaging spectral-domain OCT (EDI-
OCT) improved ability to visualize the choroid and its
thickeness [109, 110]. Patients in the acute uvetic stage had
markedly thickened choroids related to inflammatory
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infiltration and increased exudation [111, 112]. Choroidal
thickeness decreases quickly with corticosteroid treatment
[111, 112]. Da Silva et al. described that patients with long-
standing VKHD presented with thinner choroids when
compared to normal individuals [113]. Furthermore, pa-
tients with recurrent inflammation presented thicker cho-
roids when compared to patients with quiescent disease
[113, 114]. Choroidal thinning at the foveal center occurred
in an inversely proportional relation to the duration of dis-
ease [113]. EDI-OCT is a non-invasive and quantitative
method and can be used to assess the degree of choroidal
inflammatory reactions during the follow-up [114].
Ocular ultrasonography (US)
Echography may be an invaluable adjunct in diagnosis
since it allows differentiation with posterior scleritis, be-
nign reactive lymphoid hyperplasia of the uvea, diffuse
malignant melanoma and choroidal involvement in
leukemia or lymphoma [97, 115].
Ultrasonography may also be helpful when fundus view-
ing is obscured by media opacities, when presentation is
atypical and/or when extraocular signs are absent. High-
definition ocular US may demonstrate choroidal thicken-
ing in subclinical VKHD and may also aid in monitoring
response to treatment, most notably in the presence of
media opacities. However, US imaging does not add much
information in cases with subtle alterations due to its im-
aging resolution (100 μm vs 7 μm in SD-OCT and 5 μm
in EDI-OCT) Nonetheless, Forster et al. described the fol-
lowing US signs in VKHD [115]:
1. Diffuse choroidal thickening with low to medium
reflectivity;
2. Serous retinal detachments around posterior pole or
inferiorly;
3. Vitreous opacities without posterior vitreous
detachment (PVD);
4. Scleral or episcleral thickening.
Ultrasound biomicroscopy (UBM) allows detailed evalu-
ation of changes affecting the ciliary body and iris. Anter-
ior chamber shallowing was shown to occur acutely due
to ciliochoroidal detachment and ciliary body thicken-
ing. These may lead to anterior displacement of the iri-
dolenticular diaphragm, simulating acute angle-closure
glaucoma [116].
Electrophysiological testing
Electroretinogram (ERG) can be helpful in monitoring dis-
ease course as well as in demonstrating the degree of func-
tional compromise due to the inflammatory damage to
retinal components [117, 118]. Abnormal ERGs have been
described in VKHD patients with extensive chorioretinal
atrophy. Da Silva et al. demonstrated a correlation between
fundus changes and parameters of the ffERG in patients
with VKHD at late stage (with more than 6 months dur-
ation of the disease, which includes chronic and convales-
cent stages). Patients with more severe fundus-based
disease presented greater retinal dysfunction, showing
congruity between fundus appearance and the extent of
retinal damage. These authors observed diffusely dimin-
ished amplitudes in both scotopic and photopic phases,
while sparing the respective implicit times [64].
Management of Vogt-Koyanagi-Harada disease
Treatment of iridocyclitis should be performed according
to the intensity of anterior segment inflammation. Topical
corticosteroids (e.g., dexamethasone 0.1 % or prednisolone
acetate 1 % eyedrops) in combination with mydriatics/
cycloplegics (e.g., tropicamide 1.0 % eyedrops) to reduce
ciliary spasm and prevent posterior synechiae, are most
frequently used [1].
The mainstay of treatment of VKHD is prompt, high-
dose systemic corticosteroids, administered either orally
(prednisone 1–1.5 mg/kg per day) or through a short
course of intravenous delivery (methylprednisolone
1000 mg per day, intravenously, during 3 days), followed
by slow tapering of oral corticosteroids throughout a
minimum 6-month period (Fig. 6). Timing to initiate ther-
apy, corticosteroid dosing and duration of therapy are the
key factors in reducing the chance of recurrences.
Read et al. compared the use of oral corticosteroids and
the use of pulsetherapy followed by oral corticosteroids
and suggested that the route of initial administration did
not influence the outcomes measured by visual acuity
[119]. However, more recent studies show a trend to ag-
gressive high-dose corticosteroid, i.e. pulsetherapy, with
faster resolution of clinical inflammatory signs as well as
posterior segment imaging inflammatory signs (PSIIS).
Kawaguchi et al. demonstrated that medium-dose sys-
temic corticosteroid therapy may be insufficient to ad-
equately suppress ocular inflammation in VKHD. In their
case series, ICGA detected the persistence of hypofluores-
cent dark dots after 4 months in patients receiving such
regimens. Furthermore, these same patients were more
likely to develop “sunset glow fundus”. Dose as high as
0.75 mg/kg per day was necessary during the first
4 months of treatment [120]. Moreover, Chee et al. have
emphasized with about equal importance the early treat-
ment instauration [121]. This group demonstrated that
peripapillary atrophy (PPA) developed more frequently as
well as to a greater extent in patients receiving delayed
and low dose corticosteroids [121]. The same authors
showed that this finding was a marker of more severe ret-
inal dysfunction in these patients as measured by mfERG
[117].
At this point, it is needed to emphasize that a more
comprehensive approach of inflammation in post-acute
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uveitic stage of VKHD does not take into account isolate
visual acuity, but also the presence of cells in anterior
chamber and PSIIS (FA, ICGA, OCT) [61, 103, 108,
112–114]. Therefore, concerning ICGA signs, hypofluor-
escent dark dots may resolve in 4 months, while changes
in choroidal vascular permeability tend to disappear in
8 weeks due to their response to initial therapy with
high-dose corticosteroids [61, 62] Dark dots are the
most constant and most readily recordable angiographic
sign enabling choroidal inflammatory activity semi-
quantitative assessment (Fig. 4).
Some authors indicate therapy guided by ICGA in-
flammatory signs [68]. Nevertheless, a more comprehen-
sive understanding of choroidal inflammatory signs is
lacking [122, 123].
Rapid discontinuation of systemic corticosteroid may
incur in recurrences [10, 124]. Several studies have
pointed out that the minimum treatment period is
6 months. Lai et al. and Errera et al. formally demon-
strated in their retrospective studies the relevance of a
minimum of 6-month systemic and/or immunosup-
pressive drug therapy in diminishing recurrence fre-
quency and severity [124, 125]. The final treatment
duration varies widely according to the presence of
inflammation.
Immunosuppressive therapy is formally indicated in cor-
ticosteroid refractory or intolerant cases [126]. Neverthe-
less, in VKHD, the long-term systemic corticotherapy was
acceptable due to till recent notion that it presents a good
response to this therapy alone and had a good prognosis
counterbalancing the more serious immunosuppression
induced side effects [127]. However, recent literature is
pointing out to the deleterious effect on visual function of
chronic relentless choroidal inflammation and a trend to
an earlier start on systemic immunosuppression.
Some investigators have suggested immunosuppres-
sion with agents such antimetabolites, cyclosporine and
biological agents (IMT) as first-line therapy in the
treatment of VKHD. Aggressive treatment may result
in fewer complications and less recurrence. Paredes et
al. described IMT given within 6 months of diagnosis
with or without steroid was associated with a superior
visual outcome when compared to steroid as monother-
apy or with delayed additional of IMT [128]. Rao et al.
pointed out that a prospective study should be con-
ducted to validate the role of first-line immunosuppres-
sive therapy in all VKHD patients, particularly during
the acute stage of the disease, accounting for both,
potential side effects as well as little evidence available
[122].
Fig. 6 Vogt-Koyanagi-Harada disease treatment flowchart under consideration in the Uveitis Service, Hospital das Clínicas, Faculdade de Medicina,
São Paulo University, São Paulo, SP, Brazil
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Either as first-line IMT or as an adjuvant treatment in
chronic recurrent or steroid intolerant cases, use of several
IMT drugs has been reported. The choice of immunosup-
pressive agent will be more dependent on drug availability,
including cost, and tolerability than on drug-specific effi-
cacy on VKHD (Table 5). Therefore, much experience has
been gained with the wide spread-use of cyclosporine A
during the 1980s. However, cyclosporine monotherapy did
not demonstrate to be superior to other IMT drugs being
modestly effective for controlling ocular inflammation
with frequent side effects, mainly with increasing age
[129]. Of note is the long list of cyclosporin drug interac-
tions that may increase (e. g., macrolide antibiotics, anti-
fungals, diltiazem, metoclopramide, oral contraceptives,
allopurinol etc.) or decrease (e. g., barbiturates, carba-
mazepine, rifampin etc.) cyclosporine A bioavailability
[129].
Antimetabolites are drugs that inhibit nucleotide
synthesis, inhibiting the division and proliferation of in-
flammatory cells, i.e. methotrexate, azathioprine and
mycophenolate mofetil [130]. Methotrexate has been used
to control pediatric VKHD as well as adult VKHD [131].
Mycophenolate mofetil, a selective inhibitor of inosine
monophosphate dehydrogenase (an enzyme essential for
the proliferation of B and T lymphocytes), has been used
as first-line therapy in a prospective study including 19
patients leading to less recurrences and improved visual
outcome [132]. Interestingly, Urzua et al. recently eva-
luted, in a retrospective study, VKHD patients treated with
early IMT (within 6 month of diagnosis) and patients
treated with late IMT and found no differences in terms of
visual acuity improvement, complications and glucocortic-
oid sparing effect [133]. However, these authors suggested
that those with poor response to glucocorticoid therapy
could benefit with the IMT as first-line therapy and
pointed out that treatment should be individualized. Aza-
thioprine had been demonstrated to be effective by other
authors in patients with corticosteroid intolerance or
uncontrolled inflammation [134].
Case series demonstrating the efficacy of several
other treatment modalities are found in the literature
including biologics agents, such as infliximab and ritux-
imab [135–137] and intravitreal drug therapy, such as
triamcinolone, bevacizumab and fluocinolone acetonide
[138–141]. Even though intravitreal drug therapy as a
first line treatment for acute VKHD is very controver-
sial, it may be useful as an adjunt treatment in chronic
and/or recurrent stages of the disease.
In infants, methotrexate is most widely used than other
IMT and seems to be effective with minimal side effects
[11, 142–144]. In pregnancy, high-dose corticosteroids have
been used to treat VKHD successfully during the second
and third trimester of pregnancy, usually devoid complica-
tions in delivery [145–148].
New highly effective drugs with less toxicity in the
management of VKHD are continuously being searched.
One example is the strong steroid difluprednate, which
was used topically, at the onset of diagnosis, and pro-
moted complete resolution of exudative detachments
with improvement of visual acuity [149]. New biological
Table 5 Treatment of Vogt-Koyanagi-Harada disease: drugs, dosages and main side effects [126, 127]




1–1.5 mg/kg/day, gradual tapering along a
minimum 6 month-period




1 g/day during 3 days, followed by oral
prednisone
Antimetabolites
Azathioprine 1–2.5 mg/kg/day myelosuppression, gastrointestinal disturbances, infection
Methotrexate 7.5–25 mg/week nausea, vomiting, abnormalities in liver function tests, infection
Mycophenolate
mofetil
1–3 g/day gastrointestinal disturbances with diarrhea, infection
Calcineurin inhibitors
Cyclosporine A up to 5 mg/kg/day, trough 0.1–0.2 μg/L
(whole blood)
nephrotoxicity, hepatotoxicity, hyperglycemia, hypertension, hirsutism,




5 mg/kg at 0,2 and 6 weeks, followed by
5 mg/kg every 6–8 weeks
reactivation of latent tuberculosis, lymphoproliferative diseases
Adalimumab (SubQ) 40 mg every other week headache, infection
Alkylating agents
Cyclophosphamide 1–2 mg/kg/day myelossupression, hair loss, nausea, vomiting, loss of fertility, cancer risk,
infection, bladder toxicity
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agents are also being pursued such as secukinumab and
gevokizumab. Secukinumab is a full or recombinant
monoclonal antibody against IL-17 and gevokizumab is
a humanized IgG2k monoclonal antibody, which binds
to IL-1ß with high affinity and inhibits IL-1β-mediated
responses [150].
Complications
Chronic or recurrent inflammation may be associated
with the development of ocular complications, e.g. cata-
ract, glaucoma and choroidal neovascularization (CNV)
(Table 6). Other less common complications have been
reported [151–154], including cystoid macular edema,
pseudotumoral RPE proliferation, band-shaped keratopa-
thy, optic disc atrophy and phthisis bulbi.
Da Silva et al. divided VKHD patients in two groups, i.e.
early stage and late stage groups. Patients who presented
with symptoms for less than 4 weeks were grouped as
early stage; others were grouped as late stage. Patients first
seen in the late stage of disease had more ocular complica-
tions and relapses after disease onset, when compared to
those first seen in the early stage [64].
Cataract
Cataract may arise due to chronic inflammation and/or
prolonged corticosteroid therapy [155]. Cataract forma-
tion was reported in 10–42 % of patients. Cataract surgery
should be postponed until the uveitis is inactive for a
minimum period of 3 months [155–158]. Systemic corti-
costeroids (0.5–1 mg/kg/day) should be given starting 1 to
2 weeks [159] before surgery and then tapered after sur-
gery accordingly to the intensity of inflammation.. Syne-
chiolysis with or without iris-stretching maneuvers or iris
hooks may be required. Foldable hydrophobic acrylic or
heparin-surface modified polymethylmethacrylate intraoc-
ular lenses (IOL) can be safely used in eyes with VKH dis-
ease [156, 158]. Moorthy et al. reported that 68 % of 19
eyes that underwent cataract surgery have a visual acuity
of 20/40 or better [155]. In-the-bag intraocular lens im-
plantation has ultimately shifted the paradigm regarding
complicated cataract surgery, showing promising results
[160, 161].
Glaucoma
Intraocular pressure (IOP) elevation in patients with
VKHD may occur as a consequence of inflammation of
the trabecular meshwork, blockage of trabecular meshwork
by inflammatory cells, presence of peripheral anterior syne-
chiae and pupillary block with angle closure, among others.
Its prevalence ranges widely, from 6 to 45 % [162], which
may be attributable to distinct patient populations and
follow-up periods. Takahashi et al., in a retrospective study
of 217 patients with uveitic glaucoma, found that 16 % of
cases were VKHD patients; the majority had active anterior
uveitis at the time of high IOP [163]. Medical therapy
should be tried, but often these patients end up evolving to
trabeculectomy. Iwao et al., in a comparative retrospective
study of 101 eyes with uveitic glaucoma and 103 eyes with
primary open-angle glaucoma who underwent trabeculect-
omy with mitomycin C, with an average of 24 months
follow-up, reported a success rate of 71 % in patients with
uveitis and 90 % in the control group [164].
Choroidal neovascularization (CNV)
CNV may develop from inflammatory damage to Bruch’s
membrane and choriocapillaris, which leads to choroidal
and outer retinal ischemia. The ischemia may then serve as
a stimulus for proliferation of choriocapillaris endothelium.
Moreover, it has been suggested that active inflammation
induced the release of chemokines that induces angiogen-
esis. The prevalence of this complication varies from 7 to
15 % of cases and is associated with poor visual prognosis.
They are mainly localized peripapillary and subfoveal
where inflammatory foci tend to concentrate [162].
Factors predisposing for the development of CNV devel-
opment include chronic/recurrent inflammation of the
anterior segment and extensive RPE changes. Treatment
consists in control of inflammation with corticosteroids
and immunosuppressive drugs as well as use of anti-
VEGF agents (vascular endothelial growth factor) [165–
167]. The need of anti-VEGF reinjection should be evalu-
ated according to the presence of disease activity as esti-
mated on FA, ICGA and/or OCT (presence of intra- or
subretinal fluid). Mansour et al., in a retrospective multi-
center study, evaluated the visual result of intravitreal
injection of bevacizumab in patients with CNV with a
24 months follow-up. They reported aggressive CNV in
Table 6 Prevalence of the most common complications in VKHD
Author Number of eyes % Cataract % Glaucoma % CNV
Ohno [6] 102 30 20 Not available
Snyder [56] 40 16 Not available 2,5
Rubsamen [10] 52 36 45 9
Forster [183] 84 Not available 38 Not available
Moorthy [1] 130 38 Not available 12
Read [162] 101 42 27 11
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six cases of VKHD-associated CNV requiring a careful
monitoring, systemic immunomodulation and frequent
injections of anti-VEGF [167]. Some additional treatment
options that warrant investigation in the management of
VKHD-associated CNVs include photodynamic therapy,
laser photocoagulation and combination of pharmacother-
apy of anti-VEGF compounds alongside immunosuppres-
sants [168, 169]. It remains to be determined whether
agressive immunossupression or anti-VEGF therapy play
the foremost role in the treatment of CNV associated with
VKHD.
Subretinal fibrosis
Subretinal fibrosis is described in 8 to 40 % of VKHD
cases and is more common in long standing or recurrent
cases. The most common locations are peripapillary and
extrafoveal areas. Histopathologic findings reveal the pres-
ence of subretinal fibrosis, RPE cells metaplasia and chor-
oidal inflammatory cell aggregates in subretinal fibrosis
area. It is believed that cytokines, immunoglobulins and
cellular mediators produced by T-lymphocytes cause fi-
brous tissue production through interaction with the RPE
cells, Müller cells and choroidal fibrocytes. Presence of
subretinal fibrosis in patients with VKHD is associated
with a poor visual prognosis [170, 171]. Kuo et al. ob-
served subretinal fibrosis more often in Hispanics, who
develop this complication in a much shorter disease
duration than non-Hispanics (median of 6.5 months in
Hispanics and 6.5 years for non-Hispanics) [172].
Prognosis
The visual outcome in patients with VKHD has im-
proved considerably with the use of high-dose cortico-
steroids, immunosuppressant drugs and advances in the
management of complications, such as cataract, glau-
coma and CNV. The prognosis of VKHD is usually con-
sidered good with 60 % of patients having VA better
than 20/40 [1, 10].
However, several evidences point to VKHD as a much
more serious illness, i.g. more than 50 % of patients
evolves towards chronicity [1, 68, 173] and 50 % of eyes
with VKHD develop at least one complication [160].
Furthermore, a more comprehensive approach of inflam-
mation in VKHD does not take into account isolate vis-
ual acuity and characterization of inflammatory activity
based only on the presence of cells in anterior chamber
seems not to be sufficient [69]. Recent choroid imaging
advances have made possible a better identification and
quantification of inflammatory activity [61, 102, 107,
111–113].
Until recently, VKHD was considered “cured” for those
patients who were in the convalescent stage. Nevertheless,
recent studies have pointed to disease progression, even in
seemingly quiescent cases. The main evidences of this
progression are: progressive fundus depigmentation, even
in patients without obvious persistent clinical activity
[174]; worsening of visual acuity complaints in patients
apparently “cured” and with no clinical disease activity
[175]; and, presence of inflammatory cells in the choroid
of enucleated globes of patients in chronic and convales-
cent stages [51].
Even when there is resolution of acute inflammation
and recovery of good visual acuity, some patients still
have subclinical retinal dysfunction as measured by
multifocal electroretinogram (mfERG) [117, 118].
Some factors have been described as indicative of
prognosis:
I. Related to treatment: a.. Late instauration of treat-
ment from the acute disease onset: early treatment with
high-dose systemic corticosteroids resulted in less per-
sistent inflammation [176]; b.. Treatment shorter than
6 months: use of systemic corticosteroids for longer than
6 months and slow tapering were significantly associated
with good final visual acuity [10, 127, 176]; c. Treatment
with corticosteroids in suboptimal dose: patients treated
with low doses of corticosteroids in the acute stage were
more likely to have persistent inflammation [120, 121].
The extent of pigmentary changes in patients seemed to
be dependent on the amount of corticosteroid received
during the acute stage of the disease. Administering an
initial high-dose of corticosteroid may preserve more
melanocytes and may reduce the extent of pigment dam-
age [178].
II. Related to the patient: a. Younger age (controver-
sial): age at onset of the disease has been differently
linked to final VA. Poor prognosis has been associated
with older age at onset of VKHD by some authors [121,
162] and with younger age at onset by others [142, 177];
b.. Presence of HLA-DRB1*0405/0410 is more common
in patients with prolonged disease: Islam et al. investi-
gated HLA-DR4 gene variations in 46 Japanese patients,
28 with the prolonged type and 18 with the nonpro-
longed type of VKHD. Significant differences were found
in the DR4 gene variation in the two clinical subtypes.
All the patients with the prolonged type had either the
DRB1*0405 or DRB1*0410 variant, whereas 39 % of the
patients with the nonprolonged type had neither of
them. This difference in frequency was statistically
highly significant. The authors concluded that DR4 gene
variants differed significantly between the two subtypes
of VKHD, suggesting that the clinical course of VKHD is
determined partly by the patient’s HLA-DR gene vari-
ation [179].
III. Related to the disease: a.. Poor visual acuity at
presentation: better VA at presentation is associated with
a better final VA [162]. Chee et al. proposed that good VA
at one month was associated with greater likelihood of
good VA at 3 years [121]. Final VA of 20/200 or worse
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may be explained by the presence of extensive pigmentary
changes and disruption in the fundus secondary to previ-
ous inflammation and serous retinal detachment without
any other associated complications [162]. Some VKHD
patients may still have concomitant visual field loss and
subclinical retinal dysfunction caused by chorioretinal
atrophy and pigmentary changes, despite having a final
VA of 20/20 [117, 121, 162, 180]. Besides, peripapillary
atrophy is associated with visual dysfunction compared
with eyes without peripapillary atrophy [117]. Early pin-
point peripapillary hyperfluorescence on pretreatment FA
was found to be an indicator for good prognosis. In fact,
this sign was more likely to be associated with eyes imaged
early in the course of the disease than eyes imaged later
[181]; b.. Presence of complications in the initial presenta-
tion: the development of ocular complications is signifi-
cantly associated with a worse final VA [177]; c.. Increased
number of recurrences: a longer duration of disease and
higher number of recurrent episodes of inflammation are
associated with a higher risk of complications and worse
visual prognosis. A longer duration of disease and in-
creased number of recurrences expose the eye to the
harmful effects of active inflammation as well as treat-
ment, especially corticosteroids [162].
Conclusions
VKHD is a severe bilateral, granulomatous panuveitis
associated with serous retinal detachment, causing a sig-
nificant impact for patient’s life, especially considering
its frequent onset at young and working ages. Ocular
involvement undoubtedly accounts for most of the dis-
ease impact on individuals’ lives. While meningeal (neck
stiffness, headache and CSF pleocytosis) and ocular signs
are characteristic of acute stage, skin changes may be
observed later on in the course of disease. Early diagno-
sis coupled with proper treatment may result in visual
recovery. However, VKHD does require regular and
close monitoring even in apparently quiescent cases as
recent evidences lead to progressive subclinical visual
deterioration in such instances.
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